Belite Bio
BLTE
127.38
-23.64
-15.65%
Belite Bio
US · BLTE
#1866 by market cap
Listed 2022
127.38
-23.64
-15.65%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
Cantor Fitzgerald Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $270Market Newswire · 2026/8/14
-
Rating change
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Tenax Therapeutics (TENX) and Belite Bio, Inc. ADR (BLTE)TipRanks · 2026/8/31
-
Rating change
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Vertex Pharmaceuticals (VRTX) and Corcept Therapeutics (CORT)TipRanks · 2026/10/15
-
Rating change
Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $234Market Newswire · 2026/9/9
-
Rating change
H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $214Market Newswire · 2026/9/3
-
Rating change
Maxim Group Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $200Market Newswire · 2026/8/16
-
Rating change
Morgan Stanley Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $206Market Newswire · 2026/8/17
-
Earnings Flash (BLTE) Belite Bio, Inc Posts Q3 Adjusted Loss $0.60 per Share, Vs. FactSet Est of $-0.52MT Newswires · 2026/11/12
-
Belite Bio (BLTE.US) will release its financial report on November 12.Market Newswire · 2026/11/7
-
Rating change
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT)TipRanks · 2026/9/9
-
Rating change
CCORF Initiates Belite Bio(BLTE.US) With Buy Rating, Announces Target Price $303Market Newswire · 2026/9/4
-
Rating change
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE) and Daré Bioscience (DARE)TipRanks · 2026/8/16
-
Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Cuts Target Price to $221Market Newswire · 2026/10/29
-
Leerink Partners Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $215Market Newswire · 2026/11/13
-
H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $245Market Newswire · 2026/11/13
-
Rating change
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Belite Bio, Inc. ADR (BLTE)TipRanks · 2026/8/15
-
Rating change
Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $220Market Newswire · 2026/9/6
-
Rating change
A Quick Look at Today's Ratings for Belite Bio(BLTE.US), With a Forecast Between $201 to $270Market Newswire · 2026/8/15
-
Rating change
BofA Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Announces Target Price $200Market Newswire · 2026/9/3
-
Rating change
H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $245Market Newswire · 2026/9/8
-
Rating change
Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $220Market Newswire · 2026/8/14
-
H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $245Market Newswire · 2026/10/15
-
Rating change
Mizuho Securities Remains a Buy on Belite Bio, Inc. ADR (BLTE)TipRanks · 2026/8/14
-
Morgan Stanley initiates coverage on eight biotech companies in one go! PTC Therapeutics (PTCT.US) and Belite Bio (BLTE.US) receive positive ratings, with several potential blockbuster drugs highlighted.Zhitong Finance · 2026/10/20
-
Rating change
Cantor Fitzgerald Reaffirms Their Buy Rating on Belite Bio, Inc. ADR (BLTE)TipRanks · 2026/8/12
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Belite Bio discussion 0 comments